Currently released so far... 64621 / 251,287
Articles
Brazil
Sri Lanka
United Kingdom
Sweden
00. Editorial
United States
Latin America
Egypt
Jordan
Yemen
Thailand
Browse latest releases
2010/12/01
2010/12/02
2010/12/03
2010/12/04
2010/12/05
2010/12/06
2010/12/07
2010/12/08
2010/12/09
2010/12/10
2010/12/11
2010/12/12
2010/12/13
2010/12/14
2010/12/15
2010/12/16
2010/12/17
2010/12/18
2010/12/19
2010/12/20
2010/12/21
2010/12/22
2010/12/23
2010/12/25
2010/12/26
2010/12/27
2010/12/28
2010/12/29
2010/12/30
2011/01/01
2011/01/02
2011/01/04
2011/01/05
2011/01/07
2011/01/09
2011/01/11
2011/01/12
2011/01/13
2011/01/14
2011/01/15
2011/01/16
2011/01/17
2011/01/18
2011/01/19
2011/01/20
2011/01/21
2011/01/22
2011/01/23
2011/01/24
2011/01/25
2011/01/26
2011/01/27
2011/01/28
2011/01/29
2011/01/30
2011/01/31
2011/02/01
2011/02/02
2011/02/03
2011/02/04
2011/02/05
2011/02/06
2011/02/07
2011/02/08
2011/02/09
2011/02/10
2011/02/11
2011/02/12
2011/02/13
2011/02/14
2011/02/15
2011/02/16
2011/02/17
2011/02/18
2011/02/19
2011/02/20
2011/02/21
2011/02/22
2011/02/23
2011/02/24
2011/02/25
2011/02/26
2011/02/27
2011/02/28
2011/03/01
2011/03/02
2011/03/03
2011/03/04
2011/03/05
2011/03/06
2011/03/07
2011/03/08
2011/03/09
2011/03/10
2011/03/11
2011/03/13
2011/03/14
2011/03/15
2011/03/16
2011/03/17
2011/03/18
2011/03/19
2011/03/20
2011/03/21
2011/03/22
2011/03/23
2011/03/24
2011/03/25
2011/03/26
2011/03/27
2011/03/28
2011/03/29
2011/03/30
2011/03/31
2011/04/01
2011/04/02
2011/04/03
2011/04/04
2011/04/05
2011/04/06
2011/04/07
2011/04/08
2011/04/09
2011/04/10
2011/04/11
2011/04/12
2011/04/13
2011/04/14
2011/04/15
2011/04/16
2011/04/17
2011/04/18
2011/04/19
2011/04/20
2011/04/21
2011/04/22
2011/04/23
2011/04/24
2011/04/25
2011/04/26
2011/04/27
2011/04/28
2011/04/29
2011/04/30
2011/05/01
2011/05/02
2011/05/03
2011/05/04
2011/05/05
2011/05/06
2011/05/07
2011/05/08
2011/05/09
2011/05/10
2011/05/11
2011/05/12
2011/05/13
2011/05/14
2011/05/15
2011/05/16
2011/05/17
2011/05/18
2011/05/19
2011/05/20
2011/05/21
2011/05/22
2011/05/23
2011/05/24
2011/05/25
2011/05/26
2011/05/27
2011/05/28
2011/05/29
2011/05/30
2011/05/31
2011/06/01
2011/06/02
2011/06/03
2011/06/04
2011/06/05
2011/06/06
2011/06/07
2011/06/08
2011/06/09
2011/06/10
2011/06/11
2011/06/12
2011/06/13
2011/06/14
2011/06/15
2011/06/16
2011/06/17
2011/06/18
2011/06/19
2011/06/20
2011/06/21
2011/06/22
2011/06/23
2011/06/24
2011/06/25
2011/06/26
2011/06/27
2011/06/28
2011/06/29
2011/06/30
2011/07/01
2011/07/02
2011/07/04
2011/07/05
2011/07/06
2011/07/07
2011/07/08
2011/07/10
2011/07/11
2011/07/12
2011/07/13
2011/07/14
2011/07/15
2011/07/16
2011/07/17
2011/07/18
2011/07/19
2011/07/20
2011/07/21
2011/07/22
2011/07/23
2011/07/25
2011/07/27
2011/07/28
2011/07/29
2011/07/31
2011/08/01
2011/08/02
2011/08/03
2011/08/05
2011/08/06
2011/08/07
2011/08/08
2011/08/09
2011/08/10
2011/08/11
2011/08/12
2011/08/13
2011/08/15
2011/08/16
2011/08/17
2011/08/18
2011/08/19
2011/08/21
2011/08/22
2011/08/23
2011/08/24
Browse by creation date
Browse by origin
Embassy Athens
Embassy Asuncion
Embassy Astana
Embassy Asmara
Embassy Ashgabat
Embassy Apia
Embassy Antananarivo
Embassy Ankara
Embassy Amman
Embassy Algiers
Embassy Addis Ababa
Embassy Accra
Embassy Abuja
Embassy Abu Dhabi
Embassy Abidjan
Consulate Auckland
Consulate Amsterdam
Consulate Alexandria
Consulate Adana
American Institute Taiwan, Taipei
Embasy Bonn
Embassy Bujumbura
Embassy Buenos Aires
Embassy Budapest
Embassy Bucharest
Embassy Brussels
Embassy Bridgetown
Embassy Brazzaville
Embassy Bratislava
Embassy Brasilia
Embassy Bogota
Embassy Bishkek
Embassy Bern
Embassy Berlin
Embassy Belmopan
Embassy Belgrade
Embassy Beirut
Embassy Beijing
Embassy Banjul
Embassy Bangui
Embassy Bangkok
Embassy Bandar Seri Begawan
Embassy Bamako
Embassy Baku
Embassy Baghdad
Consulate Belfast
Consulate Barcelona
Embassy Cotonou
Embassy Copenhagen
Embassy Conakry
Embassy Colombo
Embassy Chisinau
Embassy Caracas
Embassy Canberra
Embassy Cairo
Consulate Curacao
Consulate Ciudad Juarez
Consulate Chiang Mai
Consulate Chennai
Consulate Chengdu
Consulate Casablanca
Consulate Cape Town
Consulate Calgary
Embassy Dushanbe
Embassy Dublin
Embassy Doha
Embassy Djibouti
Embassy Dili
Embassy Dhaka
Embassy Dar Es Salaam
Embassy Damascus
Embassy Dakar
DIR FSINFATC
Consulate Dusseldorf
Consulate Durban
Consulate Dubai
Consulate Dhahran
Embassy Guatemala
Embassy Grenada
Embassy Georgetown
Embassy Gaborone
Consulate Guayaquil
Consulate Guangzhou
Consulate Guadalajara
Embassy Helsinki
Embassy Harare
Embassy Hanoi
Consulate Hong Kong
Consulate Ho Chi Minh City
Consulate Hermosillo
Consulate Hamilton
Consulate Hamburg
Consulate Halifax
Embassy Kyiv
Embassy Kuwait
Embassy Kuala Lumpur
Embassy Kolonia
Embassy Kinshasa
Embassy Kingston
Embassy Kigali
Embassy Khartoum
Embassy Kathmandu
Embassy Kampala
Embassy Kabul
Consulate Krakow
Consulate Kolkata
Consulate Karachi
Embassy Luxembourg
Embassy Lusaka
Embassy Luanda
Embassy London
Embassy Lome
Embassy Ljubljana
Embassy Lisbon
Embassy Lima
Embassy Lilongwe
Embassy Libreville
Embassy La Paz
Consulate Leipzig
Consulate Lahore
Consulate Lagos
Mission USOSCE
Mission USNATO
Mission UNESCO
Mission Geneva
Embassy Muscat
Embassy Moscow
Embassy Montevideo
Embassy Monrovia
Embassy Mogadishu
Embassy Minsk
Embassy Mexico
Embassy Mbabane
Embassy Maseru
Embassy Maputo
Embassy Manila
Embassy Manama
Embassy Managua
Embassy Malabo
Embassy Madrid
Consulate Munich
Consulate Mumbai
Consulate Montreal
Consulate Monterrey
Consulate Milan
Consulate Merida
Consulate Melbourne
Consulate Matamoros
Consulate Marseille
Embassy Nouakchott
Embassy Nicosia
Embassy Niamey
Embassy New Delhi
Embassy Ndjamena
Embassy Nassau
Embassy Nairobi
Consulate Nuevo Laredo
Consulate Naples
Consulate Naha
Consulate Nagoya
Embassy Pristina
Embassy Pretoria
Embassy Praia
Embassy Prague
Embassy Port Of Spain
Embassy Port Moresby
Embassy Port Louis
Embassy Port Au Prince
Embassy Podgorica
Embassy Phnom Penh
Embassy Paris
Embassy Paramaribo
Embassy Panama
Consulate Peshawar
REO Mosul
REO Kirkuk
REO Hillah
REO Basrah
Embassy Rome
Embassy Riyadh
Embassy Riga
Embassy Reykjavik
Embassy Rangoon
Embassy Rabat
Consulate Rio De Janeiro
Consulate Recife
Secretary of State
Embassy Suva
Embassy Stockholm
Embassy Sofia
Embassy Skopje
Embassy Singapore
Embassy Seoul
Embassy Sarajevo
Embassy Santo Domingo
Embassy Santiago
Embassy Sanaa
Embassy San Salvador
Embassy San Jose
Consulate Surabaya
Consulate Strasbourg
Consulate St Petersburg
Consulate Shenyang
Consulate Shanghai
Consulate Sapporo
Consulate Sao Paulo
Embassy Tunis
Embassy Tripoli
Embassy Tokyo
Embassy Tirana
Embassy The Hague
Embassy Tel Aviv
Embassy Tehran
Embassy Tegucigalpa
Embassy Tbilisi
Embassy Tashkent
Embassy Tallinn
Consulate Toronto
Consulate Tijuana
Consulate Thessaloniki
USUN New York
USMISSION USTR GENEVA
USEU Brussels
US Office Almaty
US Mission Geneva
US Mission CD Geneva
US Interests Section Havana
US Delegation, Secretary
US Delegation FEST TWO
UNVIE
UN Rome
Embassy Ulaanbaatar
Embassy Vilnius
Embassy Vientiane
Embassy Vienna
Embassy Vatican
Embassy Valletta
Consulate Vladivostok
Consulate Vancouver
Browse by tag
AMGT
ASEC
AEMR
AR
APECO
AU
AORC
AS
ADANA
AJ
AF
AFIN
AMED
AM
ABLD
AFFAIRS
AMB
APER
ACOA
AG
AA
AE
ABUD
ARABL
AO
AND
ASECKFRDCVISKIRFPHUMSMIGEG
AID
AL
ASCH
AADP
AORD
ADM
AINF
AINT
ASEAN
AORG
AY
ABT
ARF
AGOA
AVIAN
APEC
ANET
AGIT
ASUP
ATRN
ASECVE
ALOW
AODE
AGUILAR
AN
ADB
ASIG
ADPM
AT
ACABQ
AGR
ASPA
AFSN
AZ
AC
ALZUGUREN
ANGEL
AIAG
AFSI
ASCE
ABMC
ANTONIO
AIDS
ASEX
ADIP
ALJAZEERA
AFGHANISTAN
ASECARP
AROC
ASE
ABDALLAH
ADCO
AMGMT
AMCHAMS
AGAO
ACOTA
ANARCHISTS
AMEDCASCKFLO
AK
ARSO
ARABBL
ASO
ANTITERRORISM
AGRICULTURE
AFINM
AOCR
ARR
AFPK
ASSEMBLY
AORCYM
AINR
ACKM
AGMT
AEC
APRC
AIN
AFPREL
ASFC
ASECTH
AFSA
ANTXON
AFAF
AFARI
AX
AMER
ASECAF
ASECAFIN
AFZAL
APCS
AGUIRRE
AIT
ARCH
AEMRASECCASCKFLOMARRPRELPINRAMGTJMXL
AOPC
AMEX
ARM
ALI
AQ
ATFN
AMBASSADOR
AORCD
AVIATION
ARAS
AINFCY
ACBAQ
AOPR
AREP
ALEXANDER
AMTC
AOIC
ABLDG
ASEK
AER
ALOUNI
AMCT
AVERY
APR
AMAT
AEMRS
AFU
AMG
ATPDEA
ALL
AORL
ACS
AECL
AUC
ACAO
BA
BR
BB
BG
BEXP
BY
BRUSSELS
BU
BD
BTIO
BK
BL
BO
BE
BMGT
BM
BN
BWC
BBSR
BTT
BX
BC
BH
BEN
BUSH
BF
BHUM
BILAT
BT
BTC
BMENA
BBG
BOND
BAGHDAD
BAIO
BP
BRPA
BURNS
BUT
BGMT
BCW
BOEHNER
BOL
BASHAR
BOU
BIDEN
BTRA
BFIN
BOIKO
BZ
BERARDUCCI
BOUCHAIB
BEXPC
BTIU
CPAS
CA
CASC
CS
CBW
CIDA
CO
CODEL
CI
CROS
CU
CH
CWC
CMGT
CVIS
CDG
CTR
CG
CF
CD
CHIEF
CJAN
CBSA
CE
CY
CB
CW
CM
CDC
COUNTRY
CLEARANCE
CHR
CT
COE
CV
COUNTER
CN
CPUOS
CTERR
CVR
CVPR
COUNTRYCLEARANCE
CLOK
CONS
CITES
COM
CONTROLS
CAN
CACS
CR
CACM
CVISCMGTCASCKOCIASECPHUMSMIGKIRF
COMMERCE
CAMBODIA
CZ
CJ
CFIS
CASCC
COUNTERTERRORISM
CAS
CONDOLEEZZA
CLINTON
CTBT
CEN
CRISTINA
CFED
CARC
CTM
CARICOM
CSW
CICTE
CJUS
CYPRUS
CNARC
CBE
CMGMT
CARSON
CWCM
CIVS
CENTCOM
COPUOS
CAPC
CGEN
CKGR
CITEL
CQ
CITT
CIC
CARIB
CVIC
CAFTA
CVISU
CHRISTOPHER
CDB
CEDAW
CNC
COMMAND
CENTER
COL
CAJC
CUIS
CONSULAR
CLMT
CBC
CIA
CIS
CEUDA
CHINA
CAC
CL
DR
DJ
DEMOCRATIC
DEMARCHE
DA
DOMESTIC
DISENGAGEMENT
DRL
DB
DE
DHS
DAO
DCM
DHSX
DARFUR
DAVID
DO
DEAX
DEFENSE
DEA
DTRO
DPRK
DARFR
DOC
DK
DTRA
DAC
DOD
DIEZ
DMINE
DRC
DCG
DPKO
DOT
DEPT
DOE
DS
DKEM
ECON
ETTC
EFIS
ETRD
EC
EMIN
EAGR
EAID
EFIN
EUN
ECIN
EG
EWWT
EINV
ENRG
ELAB
EPET
EIND
EN
EAIR
EUMEM
ECPS
ES
EI
ELTN
ET
EZ
EU
ER
EINT
ENGR
ECONOMIC
ENIV
EK
EFTA
ETRN
EMS
EPA
ESTH
ENRGMO
EET
EEB
EXIM
ECTRD
ELNT
ETRA
ENV
EAG
EREL
ENVIRONMENT
ECA
EAP
ECONOMY
EINDIR
EDUARDO
ETR
EUREM
ELECTIONS
ETRC
EICN
EXPORT
EMED
EARG
EGHG
EINF
ECIP
EID
ETRO
EAIDHO
EENV
EURM
EPEC
ERNG
ENERG
EIAD
EAGER
EXBS
ED
ELAM
EWT
ENGRD
ERIN
ECO
EDEV
ECE
ECPSN
ENGY
EL
EXIMOPIC
ETRDEC
ECCT
EINVECON
EUR
ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID
EFI
ECOSOC
EXTERNAL
ESCAP
EITC
ETCC
EENG
ERA
ENRD
EBRD
ENVR
ETRAD
EPIN
ECONENRG
EDRC
ETMIN
ELTNSNAR
ECHEVARRIA
ELAP
EPIT
EDUC
ESA
EAIDXMXAXBXFFR
EETC
EIVN
EBEXP
ESTN
EGOV
ECOM
EAIDRW
ETRDEINVECINPGOVCS
ETRDGK
ENVI
ELN
EPRT
EPCS
EPTED
ERTD
EUM
EAIDS
ETRB
EFINECONEAIDUNGAGM
EDU
EV
EAIDAF
EDA
EINTECPS
EGAD
EPREL
EINVEFIN
ECLAC
EUCOM
ECCP
ELDIN
EIDN
EINVKSCA
ENNP
EFINECONCS
EFINTS
ETC
EAIRASECCASCID
EINN
ETRP
EFQ
ECOQKPKO
EGPHUM
EBUD
ECONEINVEFINPGOVIZ
ECPC
ECONOMICS
ENERGY
EIAR
EINDETRD
ECONEFIN
ECOWAS
EURN
ETRDEINVTINTCS
EFIM
ETIO
EATO
EIPR
EINVETC
ETTD
ETDR
EIQ
ECONCS
ENRGIZ
EAC
ESPINOSA
EAIG
ENTG
EUC
ERD
EINVECONSENVCSJA
EEPET
EUNCH
ESENV
ECINECONCS
ETRDECONWTOCS
ECUN
FR
FI
FOREIGN
FARM
FAO
FK
FCSC
FREEDOM
FARC
FAS
FJ
FIN
FINANCE
FAC
FBI
FTAA
FM
FCS
FAA
FETHI
FRB
FRANCISCO
FORCE
FTA
FT
FMGT
FCSCEG
FDA
FERNANDO
FINR
FIR
FDIC
FOR
FOI
FKLU
FO
FMLN
FISO
GM
GERARD
GT
GA
GG
GR
GTIP
GB
GH
GZ
GV
GE
GAZA
GY
GJ
GEORGE
GOI
GCC
GMUS
GI
GABY
GLOBAL
GUAM
GC
GOMEZ
GUTIERREZ
GL
GOV
GKGIC
GF
GU
GWI
GARCIA
GTMO
GANGS
GIPNC
GAERC
GREGG
GUILLERMO
GASPAR
HA
HYMPSK
HO
HK
HUMAN
HR
HU
HN
HHS
HIV
HURI
HDP
HUD
HUMRIT
HSWG
HUMANITARIAN
HIGHLIGHTS
HUM
HUMANR
HL
HILLARY
HSTC
HCOPIL
HADLEY
HOURANI
HARRIET
HESHAM
HI
HNCHR
HEBRON
HUMOR
IZ
IN
IAEA
IS
IMO
ILO
IR
IC
IT
ITU
ID
IV
IMF
IBRD
IWC
ICAO
INF
ICRC
IO
IPR
IRAQI
ISO
IK
ISRAELI
IDB
INFLUENZA
IRAQ
INL
IQ
ICES
IRMO
IRAN
ISCON
IGAD
ITALY
INTERNAL
ILC
ISSUES
ICCAT
IADB
ICTY
ICTR
ITPGOV
ITALIAN
IQNV
IRDB
INMARSAT
INCB
INRB
ICJ
ISRAEL
INR
IFO
ITRA
IEA
ISPA
IOM
ITRD
IL
IHO
IFAD
IPROP
IDLI
ISCA
INV
IBB
ISPL
INRA
INTELSAT
ISAF
IRS
IEF
ITER
ISAAC
ICC
INDO
IIP
IATTC
IND
INS
IZPREL
IAHRC
IEFIN
IACI
INNP
IA
INTERPOL
IFIN
IRAJ
IX
IF
ITPHUM
ITA
IP
IZEAID
IRPE
IDA
ISLAMISTS
ITF
INRO
IBET
IDP
IRC
KMDR
KPAO
KOMC
KNNP
KFLO
KDEM
KSUM
KIPR
KFLU
KE
KCRM
KJUS
KAWC
KZ
KSCA
KDRG
KCOR
KGHG
KPAL
KTIP
KMCA
KCRS
KPKO
KOLY
KRVC
KVPR
KG
KWBG
KTER
KS
KN
KSPR
KWMN
KV
KTFN
KFRD
KU
KSTC
KSTH
KISL
KGIC
KAPO
KSEP
KDP
KFIN
KTEX
KTIA
KUNR
KCMR
KCIP
KMOC
KTDB
KBIO
KMPI
KSAF
KFEM
KUNC
KPRV
KIRC
KACT
KRMS
KNPT
KMFO
KHIV
KHLS
KPWR
KCFE
KREC
KRIM
KHDP
KVIR
KNNNP
KCEM
KIRF
KGIT
KLIG
KNUP
KSAC
KNUC
KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG
KTBT
KSCI
KIDE
KPGOV
KLPM
KTDD
KOCI
KNNC
KOMS
KBCT
KLFU
KLAB
KSEO
KICC
KJUST
KUWAIT
KSEC
KUK
KEDEM
KJRE
KMRS
KSRE
KREISLER
KSCS
KPIR
KPOA
KESS
KCOM
KWIR
KIVP
KRCM
KGLB
KPOW
KPOL
KSEAO
KNAP
KCUL
KPREL
KREF
KPRP
KICA
KPMI
KPRM
KQ
KPOP
KFSC
KPFO
KPALAOIS
KRM
KBWG
KCORR
KVRC
KR
KFTN
KTTB
KNAR
KINR
KWN
KCSY
KIIP
KPRO
KREL
KFPC
KW
KWM
KRFD
KFLOA
KMCC
KIND
KNEP
KHUM
KSKN
KT
KOMO
KDRL
KTFIN
KSOC
KPO
KGIV
KSTCPL
KSI
KNNB
KNDP
KICCPUR
KDMR
KFCE
KIMMITT
KMNP
KOMCSG
KGCC
KRAD
KCRP
KAUST
KWAWC
KCHG
KRDP
KPAS
KITA
KMSG
KTIAPARM
KPAOPREL
KWGB
KIRP
KMIG
KSEI
KLSO
KWNN
KHSA
KCRIM
KNPP
KPAONZ
KWWW
KGHA
KY
KCRCM
KGCN
KPLS
KPAOY
KRIF
KTRD
KTAO
KJU
KBTS
KWMNPHUMPRELKPAOZW
KO
KEMR
KENV
KEAI
KWAC
KFIU
KWIC
KNNO
KPAI
KTBD
KILS
KPA
KRCS
KWBGSY
KNPPIS
KNNPMNUC
KERG
KLTN
KLIP
KTLA
KAWK
KVRP
KAID
KX
KWCI
KNPR
KCFC
KNEI
KFTFN
KTFM
KCERS
KDEMAF
KMEPI
KEMS
KDRM
KBTR
KEDU
KIRL
KNNR
KMPT
KPDD
KPIN
KDEV
KAKA
KFRP
KINL
KWWMN
KWBC
KA
KOM
KWNM
KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG
KRGY
KNNF
KICR
KIFR
KWMNCS
KPAK
KDDG
KCGC
KID
KNSD
KMPF
KWMM
LY
LE
LABOR
LH
LN
LO
LAB
LT
LAURA
LTTE
LG
LU
LI
LA
LB
LOTT
LORAN
LAW
LVPR
LARREA
LEBIK
LS
LOVE
LR
LEON
LAVIN
LOG
MU
MARR
MX
MASS
MOPS
MNUC
MCAP
MTCRE
MRCRE
MTRE
MASC
MY
MK
MDC
MG
MO
MEPN
MW
MILI
MCC
MR
MEDIA
MZ
MEPP
MOPPS
MA
MAS
MI
MP
MIL
MV
MC
MD
MCA
MT
MARITIME
MOPSGRPARM
MAAR
MOROCCO
MCAPS
MOOPS
ML
MN
MEPI
MNUCPTEREZ
MTCR
MUNC
MPOS
MONUC
MAR
MGMT
MENDIETA
MARIA
MONTENEGRO
MURRAY
MOTO
MACP
MINUSTAH
MCCONNELL
MGT
MARQUEZ
MANUEL
MNUR
MF
MOHAMMAD
MAPP
MOHAMED
MNU
MFA
MTS
MLS
MIAH
MEETINGS
MERCOSUR
MED
MARAD
MNVC
MINURSO
MIK
MARK
MBM
MILITARY
MAPS
MILA
MACEDONIA
MICHEL
MASSMNUC
MUCN
MQADHAFI
MPS
MARRGH
NZ
NATO
NI
NO
NU
NG
NL
NPT
NS
NP
NA
NASA
NSF
NTTC
NAS
NEA
NANCY
NSG
NRR
NATIONAL
NKNNP
NMNUC
NSC
NC
NE
NR
NARC
NGO
NELSON
NATEU
NDP
NIH
NK
NIPP
NERG
NSSP
NSFO
NATSIOS
NFSO
NTDB
NT
NCD
NEGROPONTE
NATOIRAQ
NAR
NZUS
NCCC
NH
NAFTA
NEW
NRG
NUIN
NOVO
NATOPREL
NEY
NV
NICHOLAS
NPA
NW
NORAD
NPG
NOAA
OPRC
OPDC
OTRA
OECD
OVIP
OREP
ODC
OIIP
OAS
OSCE
OPIC
OMS
OIC
OFDA
OEXC
OFDP
OPCW
OCED
OIE
OSCI
OM
OPAD
ODIP
OPCD
OCII
ORUE
ODPC
OPPI
ORA
OCEA
OREG
OUALI
OMIG
ODAG
OPREP
OFFICIALS
OSAC
OEXP
OPEC
OFPD
OMAR
ORC
OAU
OPDP
OIL
OVIPPRELUNGANU
OSHA
OTRD
OPCR
OF
OFDPQIS
OSIC
OHUM
OTR
OBSP
OGAC
OTRAORP
OESC
OVP
ON
OES
OTAR
OCS
PREL
PGOV
PARM
PINR
PHUM
PM
PREF
PTER
PK
PINS
PBIO
PHSA
PE
PBTS
PA
PL
POL
PAK
POV
POLITICS
POLICY
PROP
PRELTBIOBA
PKO
PO
PIN
PNAT
PU
PHAM
PALESTINIAN
PTERPGOV
PGOVPREL
PKPA
PHYTRP
PP
PTEL
PREC
PENA
PRM
PELOSI
PAS
PRELAF
PRE
PUNE
PSOE
POLM
PRELKPAO
PIRF
PGPV
PARMP
PRELL
PVOV
PROV
POLUN
PS
PHUMPTER
PROG
PRELGOV
PERSONS
PERURENA
PKK
PRGOV
PH
POLITICAL
PLAB
PDEM
PCI
PRL
PREM
PINSO
PEREZ
PPAO
PERM
PETR
PERL
PBS
PGOVZI
PINT
PARMS
PCON
PETERS
PRELBR
PMIL
PSOCI
PF
PLO
PNUM
PTERM
PJUS
PNIR
PHUMKPAL
PG
PREZ
PGIC
PAO
PTBS
PROTECTION
PRELPK
PGOVENRG
PRELKPKO
PATTY
PSOC
PARTIES
PRELSP
PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ
PMIG
PAIGH
PARK
PETER
PPREL
PTERPREL
PHUS
PKPO
PGOVECON
POUS
PMAR
PWBG
PAR
PARMIR
PGOVGM
PHUH
PTE
PY
PPEL
PDOV
PGOVSOCI
PGOVPM
PRELEVU
PGOR
PRELKPAOIZ
PBTSRU
PGVO
PHUMR
PPD
PGV
PRAM
PINL
PSI
PKPAL
PPA
PTERE
PGOF
PINO
PREO
PHAS
PRHUM
PHUMA
PGO
PAC
PRESL
PORG
PKFK
PEPR
PRELP
PREFA
PNG
PFOR
PGOVLO
PHUMBA
PREK
PHUME
PHJM
POLINT
PGOVE
PHALANAGE
PARTY
PECON
PEACE
PROCESS
PLN
PEDRO
PASS
PCUL
PGGV
PSA
PGOVSMIGKCRMKWMNPHUMCVISKFRDCA
PGIV
PHUMPREL
PRFE
POGOV
PEL
PBT
PAMQ
PINF
PSEPC
POSTS
PAHO
PHUMPGOV
PGOC
PNR
RS
RP
RU
RW
RFE
RCMP
RIGHTSPOLMIL
REFORM
RO
REACTION
REPORT
ROW
ROBERT
REL
RIGHTS
RA
RELATIONS
REGION
RAFAEL
REGIONAL
RAY
ROBERTG
RPREL
RAMONTEIJELO
RM
RATIFICATION
RREL
RBI
RICE
ROOD
RODENAS
RUIZ
RELFREE
RODHAM
RGY
RUEHZO
RELIGIOUS
RODRIGUEZ
RUEUN
RELAM
RSP
RF
REO
ROSS
RENE
RUPREL
RI
REMON
RPEL
RSO
SCUL
SENV
SOCI
SZ
SNAR
SO
SP
SU
SY
SMIG
SYR
SA
SW
SG
SF
SR
SYRIA
SNARM
SPECIALIST
START
SNIG
SCI
SI
SGWI
SE
SIPDIS
SANC
SADC
SELAB
SN
SETTLEMENTS
SENVENV
SCIENCE
SENS
SPCE
SENC
SCOM
SPAS
SECURITY
SL
SOCIETY
SOSI
SENVEAGREAIDTBIOECONSOCIXR
SEN
SPECI
ST
SENVCASCEAIDID
SC
SECRETARY
STR
SNA
SOCIS
SEP
SK
SHUM
SYAI
SMIL
STEPHEN
SNRV
SKCA
SENSITIVE
SECI
SCUD
SCRM
SGNV
SECTOR
SAARC
SENVSXE
SASIAIN
SWMN
STEINBERG
SOPN
SOCR
SCRS
SILVASANDE
SWE
SARS
SNARIZ
SUDAN
SENVQGR
SNARKTFN
SAAD
SD
SAN
SIPRNET
SM
STATE
SFNV
SSA
SPCVIS
SOFA
SCULKPAOECONTU
SPTER
SKSAF
SENVKGHG
SHI
SEVN
SPSTATE
SMITH
SH
SNARCS
SNARN
SIPRS
TBIO
TW
TRGY
TSPA
TU
TPHY
TI
TX
TH
TIP
TC
TSPL
TNGD
TS
TZ
TP
TK
TURKEY
TERRORISM
TPSL
TINT
TRSY
TERFIN
TPP
TT
TF
TECHNOLOGY
TE
TAGS
TECH
TRAFFICKING
TN
TJ
TL
TO
TD
TREATY
TR
TA
TIO
THPY
TPSA
TRAD
TNDG
TVBIO
TWI
TV
TWL
TWRO
TAUSCHER
TRBY
TSPAM
TREL
TRT
TNAR
TFIN
TPHYPA
TWCH
THOMMA
THOMAS
TERROR
TRY
TBID
UK
UNESCO
UNSC
UNGA
UN
US
UZ
USEU
UG
UP
UNAUS
UNMIK
USTR
UY
UNSCD
USUN
UV
UNDC
UNRWA
UNPUOS
USAID
UNSCR
UNODC
UNHCR
UNRCR
UNDP
UNCRIME
UA
UNHRC
UNEP
UNBRO
UNCSD
UNO
UNCND
UNCHR
USTRUWR
USAU
UNICEF
UNCC
USPS
UNOMIG
UNESCOSCULPRELPHUMKPALCUIRXFVEKV
UNFICYP
UR
UNAMA
UNCITRAL
UNVIE
USTDA
USNC
USTRPS
USCC
UNEF
UNGAPL
UNSCE
USSC
UEU
UNMIC
UNTAC
USDA
UNCLASSIFIED
UNA
UNCTAD
UNMOVIC
USGS
UNFPA
UNSE
USOAS
USG
UE
UAE
UNWRA
UNION
UNCSW
UNCHS
UNDESCO
UNC
UB
UNSCS
UKXG
UNGACG
UNHR
USPTO
UNCHC
UNFCYP
UNIDROIT
WHTI
WIPO
WTRO
WHO
WI
WFP
WHA
WTO
WMO
WEET
WZ
WBG
WS
WE
WA
WEF
WAKI
WILLIAM
WHOA
WSIS
WCI
WCL
WMN
WEBZ
WW
WWBG
WMD
WWT
WWARD
WITH
WMDT
WTRQ
WCO
WALTER
WEU
WB
WBEG
Browse by classification
Community resources
courage is contagious
Viewing cable 09TAIPEI760, Taiwan Pharma: 6th PVS Underway, Big Pricing Reforms
If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:
- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #09TAIPEI760.
Reference ID | Created | Released | Classification | Origin |
---|---|---|---|---|
09TAIPEI760 | 2009-06-24 09:17 | 2011-08-23 00:00 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | American Institute Taiwan, Taipei |
VZCZCXRO7611
PP RUEHCN RUEHGH RUEHVC
DE RUEHIN #0760/01 1750917
ZNR UUUUU ZZH
P 240917Z JUN 09
FM AIT TAIPEI
TO RUEHC/SECSTATE WASHDC PRIORITY 1815
INFO RUEHOO/CHINA POSTS COLLECTIVE
RUEHHK/AMCONSUL HONG KONG 0690
UNCLAS SECTION 01 OF 04 TAIPEI 000760
STATE PLEASE PASS TO AIT/W AND EAP/RSP/TC
STATE PASS USTR/EALTBACH AND USTR/JRAGLAND
USDOC FOR 4430/ITA/MAC
SENSITIVE
SIPDIS
E.O. 12958: N/A
TAGS: ECON ETRD KIPR TW
SUBJECT: Taiwan Pharma: 6th PVS Underway, Big Pricing Reforms
Unlikely
REF: A) 2007 Taipei 2326; B) 2007 Taipei 2498; C) 2008 Taipei 950;
D) 2007 Taipei 2257; E) 2008 Taipei 572; F) 2007 Taipei 2551; G)
Taipei 73
Summary
-------
1.(SBU) The Taiwan Department of Health (DOH) Bureau of National
Health Insurance (BNHI) will announce the results of the sixth
price-volume survey (PVS) in July, and implement revised
reimbursement prices in September. BNHI is following through on a
Ma administration campaign promise to reform Taiwan's overall
Pharmaceutical Benefits Scheme (PBS), and will finalize PBS guidance
in July. Although original-drug manufacturers are unhappy with the
current draft PBS reform, industry has failed to agree on a detailed
counter-proposal.
¶2. (SBU) The Bureau of Pharmaceutical Affairs (BOPA) wants to speed
up drug-approval times by reducing documentation requirements, but
the proposed conditions for reduced documentation are insignificant,
and will likely be little-used by drug-makers. Neither separation
of dispensing and prescribing (SDP) nor patent linkage--two of
industry's long-standing goals for Taiwan--have the support of
Taiwan industry or bureaucracy, though a newly-established Taiwan
Food and Drug Administration (TFDA) may make implementing
patent-linkage in Taiwan more feasible. BNHI continues to press
industry and AIT to support LY passage of a draft law requiring
hospitals to use a standard drug-purchasing contract. End summary.
Pricing Background
------------------
¶3. (SBU) Taiwan implemented a National Health Insurance (NHI) system
in 1995, and its health-care system comprises six large public
medical centers, 16 large privately-owned medical centers, and 417
regional and district hospitals. The 22 large medical centers
dominate the pharmaceutical market, and are able to negotiate very
low drug prices. Hospitals derive up to half of these revenues from
the difference between the lower prices they have negotiated with
drug companies and the higher amounts that BNHI reimburses for the
same drugs--the source of the so-called "Black Hole" in Taiwan's
pharmaceuticals budget. BNHI, in turn, uses biannual price-volume
surveys (PVS) to collect price data from hospitals and drug makers
to use in calculating new, lower drug reimbursements.
6th PVS Underway, Big Pricing Reform Unlikely
---------------------------------------------
¶4. (SBU) Taiwan law requires hospitals that accept reimbursements
from BNHI to provide price data for all pharmaceutical purchases.
Foreign original-drug manufacturers, however, initially refused to
supply pricing data in protest over past PVS methodology. After a
pause in the PVS process to allow BNHI to collect views from
industry, hospitals, and other stakeholders on reforming Taiwan's
Pharmaceutical Benefits Scheme (PBS)--including hosting a December
2008 industry-wide conference--in February, BNHI again requested
that companies submit pricing data.
¶5. (SBU) Lawyers for the foreign drug-makers' industry group in
Taiwan, the International Research-based Pharmaceutical Manufactures
Association (IRPMA), think BNHI does not have legal grounds to
compel companies to submit price data. However, both IRPMA and
AmCham Pharmaceutical Committee leaders asked member companies to do
so as a show of industry's good will, and in March, all member
companies submitted price data to BNHI. According to BNHI Vice
President Lee Cheng-hua, the new reimbursement prices will go into
effect on September 1.
¶6. (SBU) Foreign original-drug manufacturers fear the sixth PVS,
like the five before it, will significantly reduce reimbursements
for their drugs, as well as start another round of price-cut demands
from the large hospital groups. Foreign firms, however, have been
unable to reach consensus on how to respond concretely to BNHI's PVS
methodology. They will discuss instead their ideas on reforming the
overall PBS, and their plans to commission an economic model on
pharma pricing reform in Taiwan.
PBS Reform Request Backfires
----------------------------
7.(U) In response to a Ma campaign promise to reform Taiwan's
overall Pharmaceutical Benefits Scheme (PBS) and resolve the price
TAIPEI 00000760 002 OF 004
gap problem, BNHI hosted a one-day drug-pricing conference on
December 31, 2008. Representatives from all eight major drug
industry groups plus AmCham attended the conference, which produced
a PBS reform outline now under study by BNHI.
¶8. (SBU) Over the following months, however, BNHI made no moves to
implement the proposed changes. In May, IRPMA sent a petition to
DPP Legislator and former DOH Minister Twu Shiing-zher requesting
Twu push BNHI to move forward on PBS reform. Soon afterwards, Twu
asked DOH Deputy Minister Cheng Shou-hsia to work with industry to
finalize within three months a benefit scheme reform proposal, and,
in late May, the Legislative Yuan (LY) Health and Environment
Committee passed a Twu-backed non-binding resolution calling for the
same.
¶9. (SBU) In response to the LY pressure, BNHI notified industry in
May that the Bureau plans to produce a final PBS reform plan in
July, and asked for industry's input on the current draft plan.
However, despite a series of industry-BNHI meetings over the past
month, U.S. and other original-drug makers have failed to reach
consensus on industry's PBS reform counter-proposal. On June 5,
BNHI again informed AmCham and PhRMA representatives that the Bureau
will finalize the plan by mid-July, with or without industry input.
Proposed CPP Changes Not an Improvement
---------------------------------------
¶10. (U) A Certificate of Pharmaceutical Product (CPP) is a document
provided either directly by the manufacturer or by the release
country to attest that a drug has been approved for use in the
release country, has been manufactured in compliance with food and
drug safety in that country, and is labeled in the same manner as in
the original country. In most cases, drug manufacturers will supply
a CPP from a developed economy such as the United States or European
Union market to the drug-approval authorities in a second market in
order to demonstrate the drug is already for sale in another market,
and thereby reduce the time and paperwork needed to gain approval
for sale in the second market.
¶11. (U) When a pharmaceutical company applies for regulatory
approval to market a drug in a country, the authorities in that
country typically ask manufacturers to supply one CPP as proof that
the drug is approved for sale in another market. Taiwan, however,
requires CPPs from two countries. The two-CPP requirement
disadvantages U.S. firms because BOPA regards a CPP from the
European Union as the equivalent of multiple CPPs, while the same
document from the United States counts only as one CPP. In
addition, although CPPs from all countries follow a standard,
WHO-approved format, Taiwan requires notarization of CPPs by the
Taiwan representative office in the CPP-issuing country.
¶12. (U) For the past two years, original-drug manufactures have been
urging the DOH Bureau of Pharmaceutical Affairs (BOPA) to reduce the
required number of CPPs to one in order to shorten the drug-approval
process. In response, BOPA recently announced plans to reduce the
number of required CPPs from two to one if the manufacturer conducts
two phases of clinical trials in Taiwan for the drug in question.
[Note: Pharmaceutical companies conduct clinical trials to gather
data on the safety and efficacy of new drugs or new indications for
old drugs. Typically, three phases are needed before a country's
drug authorities will grant approval, with each successive phase
including a larger group of subjects. End note.]
¶13. (SBU) The deadline to submit public comments on the proposed
changes was June 8. BOPA's Dr. Liao told econoff on June 5 that
since the CPP requirement is an administrative guideline and not a
law, once DOH decides on the final rule change, BOPA will be able to
post the requirement within two weeks.
¶14. (SBU) However, local general managers of American drug companies
tell us that because Taiwan is a relatively small market, companies
are unlikely to conduct extra trials in Taiwan just to take
advantage of the reduced CPP requirement. Instead, the companies
will simply wait for a second country to issue a CPP for the drug
and then apply for Taiwan approval. In addition, because BOPA's
plan would increase the required number of trial subjects for some
of the phases, the change will often make doing clinical trials in
Taiwan less attractive.
¶15. (SBU) IRPMA member companies instead propose relaxing the
requirement to one CPP if the company performs one phase of trials
in Taiwan, or waiving the CPP requirement completely if a company
conducts two clinical trials in Taiwan. On June 5, econoff discussed
these alternatives with Dr. Liao, who agreed the latter change would
be more attractive for companies, and urged manufacturers to take
TAIPEI 00000760 003 OF 004
advantage of the public comment period to submit their ideas.
Still Little Support for SDP
----------------------------
¶16. (SBU) Currently, when a patient sees a doctor in a Taiwan
hospital, the patient will almost always fill his prescription at
the pharmacy owned by and located in the hospital. Because Taiwan's
hospitals get much of their revenues from the difference between the
lower prices they have negotiated with drug companies and the higher
amounts that BNHI reimburses for the same drugs (ref A), hospital
administrators and doctors have an incentive to both over-prescribe
and push down contract prices for drugs. Separating dispensing and
prescribing (SDP) would eliminate this incentive.
¶17. (SBU) The U.S. and Taiwan discuss SDP under the bilateral Trade
and Investment Framework Agreement (TIFA), and Taiwan has done some
small-scale SDP pilot programs. However, Taiwan's powerful
hospitals and doctors' associations do not support any move toward
SDP because it would sap hospitals' revenues. During a recent
AIT-hosted roundtable on SDP, hospital administrators and doctors
again objected loudly to any such moves, and BOPA is not actively
planning larger SDP initiatives. Any progress toward SDP will
require continued high-level engagement with the Taiwan
authorities.
Bureaucracy Opposes Patent Linkage
----------------------------------
¶18. (SBU) Taiwan lacks a patent-linkage notification requirement and
allows generic-drug licensing before patent expiry, practices that
foreign pharmaceutical manufacturers claim allow local generic drug
makers to infringe on patent-holders' rights, as well as secure a
higher initial reimbursement price from BNHI (ref B).
¶19. (SBU) The U.S. and the Taipei American Chamber of Commerce have
pushed the Taiwan authorities to implement a U.S.-style
patent-linkage system that would continue to allow generic-drug
testing before the original drug's patent expiration, but would
include protections for the patent-holder's IPR and prevent
generic-drug makers from licensing a generic form of a patented drug
while the original patent is still valid.
¶20. (SBU) The Taiwan pharmaceutical authorities, however, do not
want to implement a U.S.-style patent linkage system. On June 5,
BOPA Director General Chi-chou Liao reiterated to econoff that BOPA
does not think Taiwan needs to introduce patent linkage, since
Taiwan's court system, including the specialized Intellectual
Property (IP) Court (ref C) can efficiently resolve such IPR
disputes. As evidence, Liao pointed to a recent case in which
Pfizer sued several local firms for releasing generic versions of
Pfizer's Lipitor prior before the original drug's patent expired.
Although Pfizer lost, Liao said the case shows the specialized court
can effectively handle drug-related IPR disputes.
BNHI Wants Industry, U.S. Support for Mandatory SC
--------------------------------------------- -----
¶21. (SBU) In response to U.S. concerns about the lack of
transparency in drug procurement by Taiwan hospitals, during the
2007 TIFA meetings in Washington, Taiwan committed to implementing a
mandatory standard contract (SC) that would require all hospitals to
use the same contract for all drug purchases (ref D).
¶22. (SBU) In September 2007, the Taiwan Executive Yuan(EY) forwarded
to the Legislative Yuan (LY) draft legislation that would require
hospitals to use an SC for pharmaceutical purchases. If the law
passes, BNHI would then finalize the text of the contract by
administrative order. The current draft SC would require full
disclosure of the actual price and allow the Bureau of National
Health Insurance (BNHI) to more accurately establish real
transaction prices in their price surveys.
¶23. (SBU) According to IRPMA Chief Operating Officer Carol Cheng,
hospitals do not support the current BNHI draft SC because it would
bring more transparency to their current pricing practices,
potentially reducing the pricing gap that funds their operations.
Foreign original-drug manufacturers also object to the proposed SC
language, which would codify a practice whereby hospitals
automatically renegotiate price contracts with drug companies
whenever BNHI announces new, lower prices.
¶24. (SBU) Without industry or hospital support, the draft
TAIPEI 00000760 004 OF 004
legislation authorizing SC has languished in the LY since 2007.
Acting BNHI President Lee has repeatedly asked IRPMA and member
companies, as well as AIT, to lobby the LY for the proposed changes.
Comment
-------
¶25. (SBU) Because Taiwan has no major new-drug makers, hospitals
that rely heavily on profits from BNHI drug reimbursements, and
consumers who are largely satisfied with the current system, there
is limited domestic support for reforming pricing practices. In
addition, with an economy in the doldrums and the national health
care system at least USD two billion in the red (ref E), financial
pressures will undercut any near-term move to spend more on
reimbursement for on-patent drugs, or increase hospital funding in
conjunction with implementing SDP.
¶26. (SBU) Therefore, the U.S.' pharma priority in Taiwan should be
support for low-cost reforms such as passing the draft standard
contract (SC) legislation and implementing patent linkage. While
U.S. industry dislikes BNHI's current SC language, the U.S. should
support passage of the bill authorizing BNHI to require that
hospitals use SCs, while working with industry and the authorities
to improve the draft SC language. Because SC is one of two
pharma-related TIFA topics, supporting SC plans could create
momentum within BNHI for addressing other pharma issues under the
TIFA rubric. In addition, although the Taiwan health bureaucracy
does not favor implementing patent linkage, the upcoming merger of
the DOH Bureau of Food Safety, Bureau of Pharmaceutical Affairs,
Bureau of Food and Drug analysis, and the National Bureau of
Controlled drugs into the Taiwan Food and Drug Administration (TFDA)
offers a chance for fresh engagement with new TFDA leadership.
¶27. (SBU) In the longer term, the U.S. should encourage Taiwan to
foster the policies and environment needed to commercialize Taiwan's
nascent biotech and biomedical industries. The authorities have
long identified biotech as a future strength of the Taiwan economy
(refs F and G), and an indigenous biotech industry developing
innovative drugs could kindle Taiwan interest in positive
pharmaceutical pricing and IP reforms. End comment.
YOUNG